The Treat FTD Fund
The Treat FTD Fund supports early-stage clinical trials of innovative treatments and biomarkers to advance therapies for frontotemporal degeneration disorders.
Funder: The Association for Frontotemporal Degeneration
Due Dates (Anticipated): October 2026 (Full application/RFP, projected)
Funding Amounts: Up to $2,500,000 per project; award size based on stage and scope of clinical trial
Summary: Supports early-stage clinical trials for innovative treatments and biomarkers in frontotemporal degeneration (FTD).
Key Information: This is a forecasted grant; all dates are projected and may change.
Description
The Treat FTD Fund, a partnership between The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer’s Drug Discovery Foundation, is designed to accelerate the development of effective treatments for frontotemporal degeneration (FTD) disorders. The program funds early-stage clinical trials that leverage advances in FTD biology, biomarker development, and preclinical research. Supported trials should incorporate strong scientific rationale, relevant biomarkers, rare disease trial designs, and robust clinical outcome measures. Both pharmacologic (e.g., small molecules, gene therapies, antibodies) and non-pharmacologic (e.g., devices) interventions are eligible, provided they are relevant to either sporadic or genetic forms of FTD. The fund encourages the use of innovative biomarkers, engagement with established research networks and patient registries, and milestone-driven project management.
